TY - JOUR
T1 - Attention-deficit hyperactivity disorder
AU - Biederman, Joseph
AU - Faraone, Stephen V.
N1 - Funding Information:
J Biederman receives consultant fees, honoraria, speakers' fees or research funding from Shire Pharmaceutical Development, Eli Lilly, Pfizer, New River Pharmaceuticals, Cephalon, Janssen, Neurosearch, the Eli Lilly Foundation, Prechter Foundation, Stanley Medical Institute, NIMH (National Institute of Mental Health), NICHD (National Institute of Child Health and Disease), and NIDA (National Institute of Drug Abuse). S V Faraone receives consultant fees, honoraria, speakers' fees or research funding from Shire Pharmaceutical Development, McNeil Consumer Pharmaceuticals, Eli Lilly, NIMH, and NIDA. Neither author was paid or asked by anyone other than The Lancet to write this Seminar.
PY - 2005/7/16
Y1 - 2005/7/16
N2 - Attention-deficit hyperactivity disorder (ADHD) is a disorder of inattention, impulsivity, and hyperactivity that affects 8-12% of children worldwide. Although the rate of ADHD falls with age, at least half of children with the disorder will have impairing symptoms in adulthood. Twin, adoption, and molecular genetic studies show ADHD to be highly heritable, and other findings have recorded obstetric complications and psychosocial adversity as predisposing risk factors. Converging evidence from animal and human studies implicates the dysregulation of frontal-subcortical-cerebellar catecholaminergic circuits in the pathophysiology of ADHD, and molecular imaging studies suggest that abnormalities of the dopamine transporter lead to impaired neurotransmission. Studies during the past decade have shown the safety and effectiveness of new non-stimulant drugs and long-acting formulations of methylphenidate and amfetamine. Other investigations have also clarified the appropriate role of targeted psychosocial treatments in the context of ongoing pharmacotherapy.
AB - Attention-deficit hyperactivity disorder (ADHD) is a disorder of inattention, impulsivity, and hyperactivity that affects 8-12% of children worldwide. Although the rate of ADHD falls with age, at least half of children with the disorder will have impairing symptoms in adulthood. Twin, adoption, and molecular genetic studies show ADHD to be highly heritable, and other findings have recorded obstetric complications and psychosocial adversity as predisposing risk factors. Converging evidence from animal and human studies implicates the dysregulation of frontal-subcortical-cerebellar catecholaminergic circuits in the pathophysiology of ADHD, and molecular imaging studies suggest that abnormalities of the dopamine transporter lead to impaired neurotransmission. Studies during the past decade have shown the safety and effectiveness of new non-stimulant drugs and long-acting formulations of methylphenidate and amfetamine. Other investigations have also clarified the appropriate role of targeted psychosocial treatments in the context of ongoing pharmacotherapy.
UR - https://www.scopus.com/pages/publications/22144455050
U2 - 10.1016/S0140-6736(05)66915-2
DO - 10.1016/S0140-6736(05)66915-2
M3 - Article
C2 - 16023516
AN - SCOPUS:22144455050
SN - 0140-6736
VL - 366
SP - 237
EP - 248
JO - The Lancet
JF - The Lancet
IS - 9481
ER -